Skip to Content

Cabazitaxel Disease Interactions

There are 7 disease interactions with cabazitaxel:


Antineoplastics (Includes cabazitaxel) ↔ infections

Severe Potential Hazard, Moderate plausibility. Applies to: Infection - Bacterial/Fungal/Protozoal/Viral

Because of their cytotoxic effects on rapidly proliferating tissues, antineoplastic agents frequently can, to varying extent, induce myelosuppression. The use of these drugs may be contraindicated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during antineoplastic therapy. Close clinical monitoring of hematopoietic function is recommended.


  1. "Product Information. Novantrone (mitoxantrone)." Immunex Corporation, Seattle, WA.
  2. "Product Information. Fludara (fludarabine)." Berlex, Richmond, CA.
  3. "Product Information. Gemzar (gemcitabine)." Lilly, Eli and Company, Indianapolis, IN.
  4. Frame JN, Dahut WL, Crowley S "Fludarabine and acute tumor lysis in chronic lymphocytic leukemia." N Engl J Med 327 (1992): 1396-7
  5. "Product Information. Taxol (paclitaxel)." Bristol-Myers Squibb, Princeton, NJ.
  6. "Product Information. Leukeran Tablets (chlorambucil)." Glaxo Welcome, Research Triangle Pk, NC.
  7. "Product Information. Doxil (doxorubicin liposomal)." Sequis Pharmaceuticals Inc, Menlo Park, CA.
  8. "Product Information. Matulane (procarbazine)." Roche Laboratories, Nutley, NJ.
  9. "Product Information. Mutamycin (mitomycin)." Bristol-Myers Squibb, Princeton, NJ.
  10. "Product Information. Leustatin (cladribine)." Ortho Biotech Inc, Raritan, NJ.
  11. "Product Information. Taxotere (docetaxel)." Rhone-Poulenc Rorer, Collegeville, PA.
  12. "Product Information. Platinol (cisplatin)." Bristol-Myers Squibb, Princeton, NJ.
  13. Sanders C, Perez EA, Lawrence HJ "Opportunistic infections in patients with chronic lymphocytic leukemia following treatment with fludarabine." Am J Hematol 39 (1992): 314-5
  14. "Product Information. Purinethol (mercaptopurine)." Glaxo Wellcome, Research Triangle Pk, NC.
  15. "Product Information. Tabloid (thioguanine)." Glaxo Wellcome, Research Triangle Park, NC.
  16. "Product Information. Idamycin (idarubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  17. "Product Information. Xeloda (capecitabine)." Roche Laboratories, Nutley, NJ.
  18. "Product Information. Methotrexate (methotrexate)." Lederle Laboratories, Wayne, NJ.
  19. "Product Information. Nipent (pentostatin)." Parke-Davis, Morris Plains, NJ.
  20. "Product Information. DTIC-Dome (dacarbazine)." Bayer, West Haven, CT.
  21. "Product Information. Ifex (ifosfamide)." Bristol-Myers Squibb, Princeton, NJ.
  22. "Product Information. Thiotepa (thiotepa)." Lederle Laboratories, Wayne, NJ.
  23. Bastion Y, Coiffier B, Tigaud JD, Espinouse D, Bryon PA "Pneumocystis pneumonia in a patient treated with fludarabine for chronic lymphocytic leukemia." Eur J Cancer 27 (1991): 671
  24. "Product Information. Adriamycin PFS (doxorubicin)." Pharmacia and Upjohn, Kalamazoo, MI.
  25. "Product Information. Alkeran Tablets (melphalan)." Glaxo Wellcome, Research Triangle Pk, NC.
  26. Schilling PJ, Vadhan-Raj S "Concurrent cytomegalovirus and pneumocystis pneumonia after fludarabine therapy for chronic lymphocytic leukemia." N Engl J Med 323 (1990): 833-4
  27. "Product Information. Hycamtin (topotecan)." SmithKline Beecham, Philadelphia, PA.
  28. "Product Information. Cytosar-U (cytarabine)." Pharmacia and Upjohn, Kalamazoo, MI.
  29. Girmenia C, Mauro FR, Rahimi S "Late listeriosis after fludarabine plus prednisone treatment." Br J Haematol 87 (1994): 407-8
  30. "Product Information. Vepesid (etoposide)." Bristol-Myers Squibb, Princeton, NJ.
  31. "Product Information. Uracil Mustard (uracil mustard)." Roberts Pharmaceutical Corporation, Eatontown, NJ.
View all 31 references

Cabazitaxel (Includes cabazitaxel) ↔ hepatic impairment

Severe Potential Hazard, Moderate plausibility. Applies to: Liver Disease

Cabazitaxel is extensively metabolized in the liver and is contraindicated in patients with severe hepatic impairment. Caution and close monitoring is recommended when prescribing this agent to patients with mild or moderate hepatic impairment and dosage reduction should be considered for these patients.


Cabazitaxel (Includes cabazitaxel) ↔ myelosuppression

Severe Potential Hazard, Moderate plausibility. Applies to: Bone Marrow Depression/Low Blood Counts, Fever, Anemia

The use of cabazitaxel is contraindicated in patients with neutrophils count less than or equal to 1,500/mm3. The use of cabazitaxel may cause bone marrow suppression manifested as neutropenia, anemia, thrombocytopenia and/or pancytopenia. Prophylaxis therapy should be considered in patients with high-risk clinical features (age >65 years, poor performance status, previous episodes of febrile neutropenia, extensive prior radiation ports, poor nutritional status, or other serious comorbidities) that predispose them to increased complications from prolonged neutropenia. Cautions should be exercised in patients using cabazitaxel with hemoglobin counts of less than 10 g/dL. It is recommended to monitor complete blood counts on a weekly basis during cycle 1 and before each treatment cycle thereafter so that the dose can be adjusted, if needed.


Cabazitaxel (Includes cabazitaxel) ↔ renal failure

Severe Potential Hazard, Moderate plausibility. Applies to: Sepsis, Dehydration, Urinary Tract Obstruction

Renal failure, sometimes with fatal outcomes has been documented with the use of cabazitaxel in clinical studies and most cases have occurred in association with sepsis, dehydration, or obstructive uropathy. Care and appropriate measures should be taken when prescribing this agent to these patients.


Cabazitaxel (Includes cabazitaxel) ↔ GI complications

Moderate Potential Hazard, Moderate plausibility. Applies to: Neutropenia, Gastrointestinal Hemorrhage, Gastrointestinal Obstruction, Peptic Ulcer

Gastrointestinal hemorrhage and perforation, ileus, enterocolitis, neutropenic enterocolitis, including fatal outcome, have been reported in patients treated with cabazitaxel. Risk may be increased with neutropenia, age, steroid use, concomitant use of NSAIDs, anti-platelet therapy or anti-coagulants, and patients with a prior history of pelvic radiotherapy, adhesions, ulceration and GI bleeding. It is recommended to monitor closely for early manifestations of serious gastrointestinal toxicity and to delay or discontinue treatment if necessary, in particular if patients experience Grade >=3 diarrhea.


Cabazitaxel (Includes cabazitaxel) ↔ hemodialysis

Moderate Potential Hazard, Moderate plausibility. Applies to: hemodialysis

Cabazitaxel is minimally excreted via the kidney and its use does not require dosage adjustment in patients with renal impairment not requiring hemodialysis. Patients presenting with end-stage renal disease should be monitored carefully during treatment with cabazitaxel.


Cabazitaxel (Includes cabazitaxel) ↔ pulmonary impairment

Moderate Potential Hazard, Moderate plausibility. Applies to: Infection - Bacterial/Fungal/Protozoal/Viral, Interstitial Pneumonitis, Pulmonary Impairment

Interstitial lung disease/pneumonitis and acute respiratory distress syndrome have been reported with the use of cabazitaxel. Patients with underlying lung disease may be at higher risk for these events. Acute respiratory distress syndrome may occur in the setting of infection. Treatment interruption or discontinuation may be necessary if new or worsening of pulmonary symptoms develop. Close monitoring is recommended. The benefits of resuming therapy should be carefully evaluated.

Cabazitaxel drug interactions

There are 346 drug interactions with cabazitaxel

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.